A serious liver disease that affects millions of people around the world may soon have a powerful new treatment option.
Researchers at the University of California San Diego have developed a drug that could help stop, and possibly reverse, a dangerous condition known as MASH, a severe form of fatty liver disease that is closely linked to obesity and type 2 diabetes.
MASH, short for metabolic dysfunction-associated steatohepatitis, occurs when excess fat builds up in the liver and triggers inflammation and damage. Over time, the disease can cause scarring of the liver, known as fibrosis.
If left untreated, it can progress to cirrhosis, liver failure, or liver cancer. Because symptoms often do not appear until significant damage has already occurred, MASH is frequently called a “silent” disease.
The condition has become a growing global health concern. Rising rates of obesity, type 2 diabetes, and metabolic disorders have led to a sharp increase in fatty liver disease worldwide.
Health experts estimate that more than 100 million Americans have some form of fatty liver disease, and roughly one in four adults globally may be affected. Many people are unaware they have the condition until it is discovered during routine medical testing or after serious complications develop.
Now, researchers believe they may have found a new way to tackle the disease at its source.
The experimental drug, called ION224, was designed to target an enzyme in the liver known as DGAT2. This enzyme plays a key role in the production and storage of fat within liver cells. When too much fat accumulates, it can trigger inflammation and damage that gradually destroys healthy liver tissue.
By blocking DGAT2, ION224 reduces the liver’s ability to store excess fat. As fat levels decrease, inflammation also declines. Since both fat buildup and inflammation are major drivers of liver damage in MASH, scientists believe targeting this pathway could provide significant benefits for patients.
The research was led by Dr. Rohit Loomba and published on August 23, 2025, in The Lancet, one of the world’s leading medical journals. Dr. Loomba explained that the treatment addresses the underlying biological processes responsible for the disease rather than simply managing symptoms.
To evaluate the drug’s effectiveness, researchers conducted a Phase IIb clinical trial involving 160 adults in the United States who had MASH and evidence of liver fibrosis. Clinical trials at this stage are designed to determine whether a treatment is effective and safe before larger studies are performed.
Participants were randomly assigned to receive either monthly injections of ION224 or a placebo for one year. Different groups received different doses of the drug so researchers could compare the results.
The findings were encouraging. Approximately 60% of patients receiving the highest dose of ION224 experienced meaningful improvements in their liver health compared with participants receiving the placebo. The improvements included reductions in disease activity and signs that liver damage was becoming less severe.
One particularly important finding was that the benefits appeared even among participants who did not lose weight during the study.
This suggests that the drug works independently of weight loss, which is significant because many patients struggle to achieve and maintain substantial weight reduction. The medication could potentially be used alongside lifestyle changes or other treatments to provide additional benefits.
Researchers also reported that no serious side effects were linked to the drug during the trial. Safety is a major concern for any new treatment, especially for conditions that may require long-term management. The favorable safety profile observed in the study provides additional optimism as the drug moves into later stages of testing.
The development of effective treatments for MASH has become increasingly urgent. Although lifestyle changes such as healthy eating, exercise, and weight loss remain important, many patients continue to experience disease progression despite these efforts.
As the disease advances, treatment options become limited, and some patients eventually require liver transplantation.
Dr. Loomba, who directs a specialized liver disease research center at UC San Diego, believes the findings represent a significant step forward. If future studies confirm the current results, ION224 could become one of the first therapies capable of directly slowing or reversing liver damage before severe complications occur.
The potential benefits extend beyond individual patients. Earlier treatment of MASH could reduce healthcare costs associated with hospital admissions, advanced liver disease, cancer treatment, and liver transplantation. Preventing severe disease could improve quality of life while easing the burden on healthcare systems.
While the results are highly promising, researchers caution that more work remains to be done. The next stage will involve a larger Phase III clinical trial, which is designed to confirm both safety and effectiveness in a much larger patient population. Success in Phase III testing would move the drug significantly closer to regulatory approval and public availability.
For the millions of people living with fatty liver disease, the findings offer renewed hope. A treatment that directly targets the root causes of MASH could transform how the disease is managed and potentially prevent countless cases of liver failure, cirrhosis, and liver cancer in the future.
The study was published in The Lancet.
Copyright © 2026 Knowridge Science Report. All rights reserved.
